TNFRSF21 Polyclonal Antibody

SKU: AN006810L

Size::25μL

Storage:Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.

Shipping:The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended.

Exp date:12 months

Category ID_II:Primary Antibodies

Category ID_III:Polyclonal Antibodies

Abbreviation:TNFRSF21

Target Synonym:UNQ;PRO;Death Receptor;Tumor Necrosis Factor Receptor Superfamily Member;TNFRSF;CD358;Death Receptor 6;Tumor Necrosis Factor Receptor Superfamily Member 21;DR6;TNFRSF21;UNQ437;PRO868; DR6;AA959878 Protein;BM 018;BM018;DR 6;DR6 Protein;MGC31965;OTTHUMP00000039915;R74815 Protein;TNFR related death receptor 6;TNFRSF 21;TNFRSF21 protein;TNR21;TR7 Protein;Tumor necrosis factor receptor superfamily member 21 precursor

Research Areas:Cell Biology

Conjugation:Unconjugated

Host:Rabbit

Species reactivity:Human

Application:WB

Isotype:IgG

Clonality:Polyclonal

Clone NO.:

UNIProt ID:O75509

Accession:

Background:Death Receptor 6 (DR6), also known as TNFRSF21 and CD358, is a type I transmembrane protein in the TNF receptor superfamily. Human DR6 consists of a 308 amino acid (aa) extracellular domain (ECD) with four cysteine‑rich motifs, a 21 aa transmembrane segment, and a 285 aa palmitylated cytoplasmic region that contains one death domain. Within the ECD, human and mouse DR6 share 82% aa sequence identity. DR6 is expressed as an approximately 110 kDa molecule that carries extensive N‑linked and O‑linked glycosylation in its extracellular region. Among hematopoietic cells, DR6 is expressed on monocytes, resting CD4+ T cells, and pro‑, pre‑, and naïve B cells. DR6 knockout mice exhibit a Th2‑biased immune response characterized by exaggerated Th2 and B cell responsiveness in combination with reduced Th1 cell responsiveness and inflammatory leukocyte infiltration. DR6 knockout mice are resistant to induced airway inflammation and experimental autoimmune encephalitis but more susceptible to severe graft versus host disease. DR6 is also expressed on developing neurons where it can bind a shed 35 kDa N‑terminal fragment of APP or a fragment of APLP2. This APP fragment is generated following deprivation of neurotrophic factors, and its binding to DR6 triggers DR6‑mediated axonal pruning. DR6 is constitutively expressed on some prostate cancer cells and can be induced by TNF‑ alpha on others.

Concentration:1 mg/mL

Immunogen:Recombinant Human TNFRSF21 protein expressed by Mammalian

Buffer:PBS with 0.05% proclin 300, 1% protective protein and 50% glycerol,pH7.4

Purification method:Antigen Affinity Purification

Dilution:WB 1:500-1:1000

Calculated MW:72 kDa

ObservedMW:70 kDa